Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega’s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $211M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Terra Magn... | terramagnu... |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.04.2021 | Series C | $126M | - |
| 31.07.2020 | - | $85M | - |
Mentions in press and media 18
| Date | Title | Description |
| 12.03.2025 | The Dawn of Autonomous Science: Lila Sciences and the Future of Discovery | In the world of scientific research, a new player has emerged, promising to change the game. Lila Sciences, a startup born from the innovative incubator Flagship Pioneering, has raised a staggering $200 million in seed funding. This infusio... |
| 10.03.2025 | Lila Sciences raises $200M to accelerate autonomous scientific research Your vote of support is important to us and it helps us keep the content FREE. One click below supports our mission to provide f... | Artificial intelligence-powered scientific discovery startup Lila Sciences is the latest company to emerge from Flagship Pioneering Inc.’s biotechnology incubator, and it’s backed by a staggering $200 million in seed funding. The startup, w... |
| 03.10.2024 | A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore | Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science... |
| 06.08.2024 | Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner | Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that global... |
| 06.03.2024 | Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 | - |
| 10.09.2021 | Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives | |
| 29.07.2021 | Omega Therapeutics Announces Pricing of Initial Public Offering | |
| 23.06.2021 | Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar | |
| 31.03.2021 | Omega Therapeutics secures $126M to treat cancer and other diseases | Omega Therapeutics has raised a $126 million Series C from investors including Flagship Pioneering, Fidelity Management and Research, BlackRock and Point72. Based in the Boston area, the company is developing therapies to treat cancer, infl... |
| 30.03.2021 | Biotech Startup Omega Therapeutics Grabs $126 Million | Omega Therapeutics Inc. has raised $126 million in venture financing to treat diseases by controlling specific genes, part of a broader biotechnology-industry push to develop genomic medicines. Genomic medicines are poised to grow in import... |
Show more